用于心脏肿瘤学临床前心脏毒性筛查的人诱导多能干细胞衍生心肌细胞
Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes for Preclinical Cardiotoxicity Screening in Cardio-Oncology.
作者信息
Shead Kyle D, Huethorst Eline, Burton Francis, Lang Ninian N, Myles Rachel C, Smith Godfrey L
机构信息
School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, United Kingdom.
出版信息
JACC CardioOncol. 2024 Sep 10;6(5):678-683. doi: 10.1016/j.jaccao.2024.07.012. eCollection 2024 Oct.
• hiPSC-CM offer an alternative to in vivo models for predicting cardiotoxicity. • hiPSC-CM monolayers detect pro-arrhythmic effects; inotropic detection is less established. • Cardiac spheroids and engineered tissue may suit chronic cardiotoxicity studies (>2 weeks). • Cardiac assays with non-myocyte cells may be key to identifying some cardiotoxicity forms. • hiPSC-CM technologies are well placed to develop patient-specific assays in the future.
• 人诱导多能干细胞来源的心肌细胞（hiPSC-CM）为预测心脏毒性的体内模型提供了一种替代方案。
• hiPSC-CM单层可检测促心律失常作用；变力性检测的方法尚不完善。
• 心脏球体和工程组织可能适用于慢性心脏毒性研究（>2周）。
• 非心肌细胞的心脏检测可能是识别某些心脏毒性形式的关键。
• hiPSC-CM技术在未来很适合开发针对患者的检测方法。
Zotero 插件